Document is current
Any future updates will be listed below
-
Authors
Boye, Kristina Secnik https://orcid.org/0000-0002-5953-5929
Poon, Jiat Ling https://orcid.org/0000-0001-7038-2102
Landó, Laura Fernández https://orcid.org/0000-0002-0969-6214
Sapin, Hélène https://orcid.org/0000-0003-2602-8450
Huh, Ruth https://orcid.org/0000-0002-7725-088X
Wang, Mianbo https://orcid.org/0009-0007-7148-2827
Williamson, Suzanne https://orcid.org/0009-0005-2461-1919
Patel, Hiren https://orcid.org/0000-0003-2463-4916
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 29 February 2024
Accepted: 1 July 2024
First Online: 15 July 2024
Declarations
:
: Kristina Secnik Boye, Jiat Ling Poon, Laura Fernandez Lando, Helene Sapin, Ruth Huh, and Hiren Patel are minor stockholders of Eli Lilly and Company. Mianbo Wang and Suzanne Williamson work as consultants for Eli Lilly and Company.
: The study protocol was approved by the Ethical Review Board at each site (Supplementary Material Table ), including the Ethical Review Board at the Principal Investigator site (Advarra Inc., Columbia, Maryland, US). This study was conducted in accordance with consensus ethical principles derived from international guidelines including the Declaration of Helsinki of 1964 and its later amendments, Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable International Council for Harmonisation Good Clinical Practice guidelines and applicable local laws and regulations. All participants provided written informed consent. This article is based on a previously conducted study and does not contain any new studies with human participants or animals performed by any of the authors.
